Clinical Trials

Comparison of Individualized Anti-Cancer Vaccine Methods in Advanced Hepatocellular Carcinoma Subjects

Status: Pending Regulatory Approval

Code: ITL-023-HCC-BKK-CRYRFA

Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck

Status:   Pending Import License

Code: ITL-020-HENK-VAXPII

Increased Frequency of AlloStim® Dosing in Combination With Cryoablation in Metastatic Colorectal Cancer

Status:   Recruiting

Code: ITL-019-CORK-CRYVAC

An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects

Status:   Recruiting

Code: ITL-022-HCC-BKK-VAX+S

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more